Volume 26, Number 4—April 2020
Research
Genomic Insight into the Spread of Meropenem-Resistant Streptococcus pneumoniae Spain23F-ST81, Taiwan
Table 1
Serotype distribution and penicillin and meropenem susceptibility rates of invasive Streptococcus pneumoniae isolates from 2 tertiary hospitals in Taiwan, 2013−2017*†
Serotype | Isolates, no. | No. (%) isolates |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Meropenem |
Penicillin, meningitis |
Penicillin, nonmeningitis |
||||||||||
S | I | R | S | I | R | S | I | R | ||||
PCV7 | ||||||||||||
4 | 4 | 3 (75) | 1 (25) | 0 | 3 (75) | NC | 1 (25) | 4 (100) | 0 | 0 | ||
6B | 8 | 6 (75) | 2 (25) | 0 | 1 (12.5) | NC | 7 (87.5) | 8 (100) | 0 | 0 | ||
9V | 2 | 2 (100) | 0 (0) | 0 | 2 (100) | NC | 0 | 2 (100) | 0 | 0 | ||
14 | 18 | 4 (22.2) | 14 (77.8) | 0 | 1 (5.6) | NC | 17 (94.4) | 18 (100) | 0 | 0 | ||
18C | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
19F | 18 | 3 (16.7) | 8 (44.4) | 7 (38.9) | 1 (5.6) | NC | 17 (94.4) | 14 (77.8) | 4 (22.2) | 0 | ||
23F | 10 | 5 (50) | 5 (50) | 0 | 0 | NC | 10 (100) | 10 (100) | 0 | 0 | ||
Subtotal |
60 |
23 (38.3) |
30 (50) |
7 (11.7) |
8 (13.3) |
NC |
52 (86.7) |
56 (93.3) |
4 (6.7) |
0 |
||
PCV13−non-PCV7 | ||||||||||||
1 | 1 | 0 | 1 (100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
3 | 15 | 15 (100) | 0 | 0 | 9 (60) | NC | 6 (40) | 15 (100) | 0 | 0 | ||
5 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
6A | 7 | 3 (42.9) | 4 (57.1) | 0 | 1 (14.3) | NC | 6 (85.7) | 7 (100) | 0 | 0 | ||
7F | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
19A | 36 | 4 (11.1) | 13 (36.1) | 19 (52.8) | 0 | NC | 36 (100) | 31 (86.1) | 5 (13.9) | 0 | ||
Subtotal |
59 |
22 (37.3) |
18 (30.5) |
19 (32.2) |
10 (16.9) |
NC |
49 (83.1) |
54 (91.5) |
5 (8.5) |
0 |
||
PPV23−non-PCV13 | ||||||||||||
8 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
10A | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
11A | 4 | 2 (50) | 1 (25) | 1 (25) | 2 (50) | NC | 2 (50) | 4 (100) | 0 | 0 | ||
15B | 17 | 1 (5.9) | 8 (47.1) | 8 (47.1) | 0 | NC | 17 (100) | 16 (94.1) | 1 (5.9) | 0 | ||
20 | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
22F | 3 | 3 (100) | 0 | 0 | 3 (100) | NC | 0 | 3 (100) | 0 | 0 | ||
33F | 0 | 0 | 0 | 0 | 0 | NC | 0 | 0 | 0 | 0 | ||
Subtotal |
24 |
6 (25) |
9 (37.5) |
9 (34.6) |
5 (19.2) |
NC |
19 (79.2) |
23 (95.8) |
1 (3.9) |
0 |
||
NVT | ||||||||||||
6C | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
7B/C | 2 | 2 (100) | 0 | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
9A/L | 2 | 2 (100) | 0 | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
11B | 1 | 1 (100) | 0 | 0 | 1 (100) | NC | 0 | 1 (100) | 0 | 0 | ||
11C | 1 | 1 (100) | 0 | 0 | 1 (100) | NC | 0 | 1 (100) | 0 | 0 | ||
12 | 2 | 0 | 2 (100) | 0 | 0 | NC | 2 (100) | 2 (100) | 0 | 0 | ||
15A | 20 | 7 (35) | 12 (60) | 1 (5) | 2 (10) | NC | 18 (90) | 19 (95) | 1 (5) | 0 | ||
15C | 12 | 2 (16.7) | 8 (66.7) | 2 (16.7) | 2 (16.7) | NC | 10 (83.3) | 10 (100) | 0 | 0 | ||
15F | 1 | 0 | 1(100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
18F | 1 | 0 | 1 (100) | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
19B | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
23A | 14 | 10 (71.4) | 3 (21.4) | 1 (7.2) | 0 | NC | 14 (100) | 14 (100) | 0 | 0 | ||
23B | 2 | 1 (50) | 1 (50) | 0 | 0 | NC | 2 (100) | 2 (100) | 0 | 0 | ||
35A/C | 2 | 1 (50) | 1 (50) | 0 | 1 (50) | NC | 1 (50) | 2 (100) | 0 | 0 | ||
35B | 1 | 1 (100) | 0 | 0 | 0 | NC | 1 (100) | 1 (100) | 0 | 0 | ||
Subtotal | 63 | 30 (47.6) | 29 (46) | 4 (6.3) | 9 (14.3) | NC | 54 (85.7) | 58 (98.3) | 1 (1.7) | 0 |
*I, intermediate; NC, not calculated; NVT, nonvaccine type; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; R, resistant; S, susceptible.
†MICs for meropenem: S, <0.25; I, 0.5; R, >1; for penicillin, meningitis: S, <0.06; R, >0.12; and for penicillin, nonmeningitis: S, <2; I, 4; R, >8.
1These first authors contributed equally to this article.